Ipilimumab in the treatment of metastatic melanoma: A summary of recent studies

Research output: Contribution to journalArticlepeer-review


In the last 20 years, the survival and quality of life outcomes for patients with metastatic melanoma have been poor, with unsatisfactory results of chemotherapy and immunotherapy-based regimens. No drug or combination of drugs had any impact on survival until 2011, when ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4), was approved for clinical use. Phase III trials have shown, for the first time ever, an overall survival benefit of ipilimumab compared with standard treatment, with a manageable toxicity profile. This review will discuss the mechanism of action of ipilimumab and the clinical trials that led to its approval. Copyright - Il Pensiero Scientifico Editore.

Original languageEnglish
Issue number6
Publication statusPublished - Nov 2013


  • Anti-CTLA-4
  • Immunotherapy
  • Ipilimumab
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Ipilimumab in the treatment of metastatic melanoma: A summary of recent studies'. Together they form a unique fingerprint.

Cite this